Sevuparin

Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego

Independent DSMB endorses inclusion of adolescents in ongoing clinical study with sevuparin in Sickle Cell Disease

What’s going on at Modus Therapeutics

Modus’ CEO, Christina Herder, to present the company at the 5th Annual Sickle Cell Disease Therapeutics Conference in New York.

Modus Therapeutics to present at SCD Therapeutics Conference in New York

Modus’ CEO, Christina Herder, presented the company at the 5th Annual Sickle Cell Disease Therapeutics.

Modus Therapeutics to present at SCD Therapeutics Conference in New York

In her presentation, Dr Herder will outline Modus Therapeutics’s development plans for sevuparin, a novel drug that it believes could offer a significant improvement of treatments in SCD.

Modus Therapeutics poster presentation at EHA Congress

Modus Therapeutics’s submission is entitled: ‘Sevuparin Demonstrates Binding to Key Adhesion Receptors Involved in Pathogenesis of Sickle-Cell Disease’.

Interviewing the Swedish Biotech that started the first Phase II Trial in Bahrain

I was curious to interview Christina Herder, the CEO of Modus Therapeutics, which launched a Phase II trial in co-operation with Bahrain and the rest of the Emirates.

Innovative Bahraini Deal Inked For Sickle Cell Therapy

Modus Therapeutics AB announced Feb. 16, the Middle East University has shouldered some of the risk of developing sevuparin.